What is Seres Therapeutics Inc's earnings per share (EPS)?

Seres Therapeutics Inc (MCRB) reported diluted earnings per share of $0.64 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Seres Therapeutics Inc Financials

MCRB

FY2025 annual

Revenue $789K YoY not available

Net Income $5.7M +4088.2% YoY

EPS (Diluted) $0.64 YoY not available

Free Cash Flow $865K +100.6% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Seres Therapeutics Inc (MCRB) reported $789K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MCRB FY2025 2026-08-05

Seres still runs on research spending and a capital-supported operating model, with sales far too small to carry the cost base.

Reported profitability in FY2025 breaks from operating reality: net income turned positive at $5.7M and free cash flow at $865K. Because revenue was only $789K while operating loss stayed at -$94.0M, the improvement did not come from selling enough product to fund the business and says more about accounting and cash timing than commercial scale.

Loss reduction has come mainly from shrinking the expense base, not top-line scale: research and development fell from $109.7M to $49.1M across the recent period. That pattern makes the narrower operating loss look like burn control and program resizing, rather than evidence that revenue has started absorbing fixed costs.

Liquidity improved materially as cash increased from $30.8M to $45.8M. Balance-sheet pressure also eased because total liabilities fell from $126.0M to $94.0M, giving the company more room to finance research without the near-term squeeze visible a year earlier.

Financial Health Signals

Financial health score not available

Seres Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-11.53

Seres Therapeutics Inc scores -11.53, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($46.8M) relative to total liabilities ($94.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/7

Seres Therapeutics Inc passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.20x

For every $1 of reported earnings, Seres Therapeutics Inc generates $0.20 in operating cash flow ($1.1M OCF vs $5.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$789K

5Y CAGR-52.7%

Seres Therapeutics Inc generated $789K in revenue in fiscal year 2025.

EBITDA

-$89.8M

YoY+22.5%

Seres Therapeutics Inc's EBITDA was -$89.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.5% from the prior year.

Net Income

$5.7M

YoY+4088.2%

Seres Therapeutics Inc reported $5.7M in net income in fiscal year 2025. This represents an increase of 4088.2% from the prior year.

EPS (Diluted)

$0.64

Seres Therapeutics Inc earned $0.64 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

$865K

YoY+100.6%

Seres Therapeutics Inc generated $865K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 100.6% from the prior year.

Cash & Debt

$45.8M

YoY+48.6%

5Y CAGR-17.0%

10Y CAGR-4.7%

Seres Therapeutics Inc held $45.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

10M

YoY+10.5%

Seres Therapeutics Inc had 10M shares outstanding in fiscal year 2025. This represents an increase of 10.5% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

12.9%

YoY+11.9pp

Seres Therapeutics Inc's ROE was 12.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 11.9 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$49.1M

YoY-24.1%

5Y CAGR-11.5%

10Y CAGR+2.6%

Seres Therapeutics Inc invested $49.1M in research and development in fiscal year 2025. This represents a decrease of 24.1% from the prior year.

Capital Expenditures

$252K

YoY-33.7%

5Y CAGR-15.7%

10Y CAGR-24.8%

Seres Therapeutics Inc invested $252K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 33.7% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

MCRB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MCRB annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Revenue	N/A	$789K	$0	$0-100.0%	$7.1M-95.1%	$144.9M+336.3%	$33.2M-3.7%	$34.5M+22.1%	$28.3M-11.9%	$32.1M+47.5%	$21.8M	$0	N/A	N/A
R&D Expenses	N/A	$49.1M-24.1%	$64.6M-45.1%	$117.6M+7.2%	$109.7M-22.7%	$141.9M+56.7%	$90.6M+13.0%	$80.1M-16.5%	$96.0M+7.3%	$89.5M+9.1%	$82.0M+115.2%	$38.1M+255.4%	$10.7M+123.1%	$4.8M
SG&A Expenses	N/A	$39.2M-26.4%	$53.2M-31.4%	$77.5M+10.3%	$70.3M+1.4%	$69.3M+125.1%	$30.8M+24.4%	$24.7M-24.1%	$32.6M-4.2%	$34.0M+4.4%	$32.6M+94.6%	$16.8M+284.1%	$4.4M+250.0%	$1.2M
Operating Income	N/A	-$94.0M+22.5%	-$121.3M+37.8%	-$195.1M-8.4%	-$179.9M-179.0%	-$64.5M+26.8%	-$88.1M-22.6%	-$71.9M+28.3%	-$100.3M-9.7%	-$91.4M+1.6%	-$92.8M-69.2%	-$54.9M-263.7%	-$15.1M-149.2%	-$6.1M
Interest Expense	N/A	$0	$0-100.0%	$2.5M-59.0%	$6.0M+106.9%	$2.9M-0.5%	$2.9M+482.5%	$502K	N/A	$1.6M+26.2%	$1.3M+1418.1%	$83K	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	$5.7M+4088.2%	$136K+100.1%	-$113.7M+54.5%	-$250.2M-281.5%	-$65.6M+26.4%	-$89.1M-26.8%	-$70.3M+29.0%	-$98.9M-10.7%	-$89.4M+2.4%	-$91.6M-67.2%	-$54.8M-227.8%	-$16.7M-173.8%	-$6.1M
EPS (Diluted)	—	$0.64	$0.00	-$17.77	-$2.31-220.8%	-$0.72+35.7%	-$1.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$736K+105.6%	$358K	N/A	$351K	$0	$0	N/A	$0
R&D Expenses	$9.1M-30.7%	$13.2M	N/A	$12.6M-2.5%	$12.9M+9.5%	$11.8M	N/A	$16.5M
SG&A Expenses	$7.1M-12.5%	$8.1M	N/A	$9.5M-7.6%	$10.3M-13.8%	$11.9M	N/A	$12.7M
Operating Income	-$21.3M-1.8%	-$20.9M	N/A	-$22.5M+9.7%	-$24.9M+8.6%	-$27.2M	N/A	-$29.2M
Interest Expense	N/A	N/A	N/A	N/A	$0	$0	N/A	$0
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	$4.6M+123.0%	-$19.9M	N/A	$8.2M+141.3%	-$19.9M-160.8%	$32.7M	N/A	$88.8M
EPS (Diluted)	$0.47+122.6%	-$2.08	N/A	$0.94+141.4%	-$2.27	$3.75	N/A	$11.63

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

MCRB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MCRB annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Total Assets	$138.2M-1.2%	$139.8M-61.0%	$358.6M+2.8%	$348.8M-1.7%	$354.9M+3.5%	$342.9M+158.9%	$132.4M+9.9%	$120.5M-36.4%	$189.5M-30.5%	$272.6M+25.7%	$216.9M+84.8%	$117.3M	N/A
Current Assets	$49.4M+27.7%	$38.7M-78.0%	$175.4M-9.9%	$194.8M-35.9%	$303.6M+13.0%	$268.8M+168.3%	$100.2M+8.1%	$92.7M-40.2%	$155.1M-21.8%	$198.4M-4.5%	$207.6M+81.7%	$114.2M	N/A
Cash & Equivalents	$45.8M+48.6%	$30.8M-75.9%	$128.0M-21.5%	$163.0M-9.4%	$180.0M+55.1%	$116.0M+78.2%	$65.1M-24.1%	$85.8M+137.8%	$36.1M-33.8%	$54.5M-26.2%	$73.9M-35.3%	$114.2M+6803.6%	$1.7M
Inventory	N/A	N/A	$29.6M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$157K	$0	N/A	N/A	N/A	$9.4M+425.9%	$1.8M	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$94.0M-25.4%	$126.0M-68.8%	$403.5M+19.4%	$338.0M+51.3%	$223.4M+32.8%	$168.2M-7.0%	$180.8M+7.3%	$168.5M+30.8%	$128.8M-8.0%	$140.0M+1116.9%	$11.5M-92.0%	$144.1M	N/A
Current Liabilities	$19.3M-53.1%	$41.2M-58.2%	$98.7M+15.3%	$85.6M+4.1%	$82.3M+77.2%	$46.4M+0.9%	$46.0M+9.4%	$42.0M+32.9%	$31.6M+3.8%	$30.5M+178.9%	$10.9M+114.0%	$5.1M	N/A
Long-Term Debt	N/A	N/A	$110.0M+120.0%	$50.0M+107.9%	$24.1M-3.8%	$25.0M0.0%	$25.0M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$44.2M+220.8%	$13.8M+130.7%	-$44.9M-516.0%	$10.8M-91.8%	$131.5M-24.7%	$174.8M+461.6%	-$48.3M-0.6%	-$48.0M-179.2%	$60.7M-54.2%	$132.6M-35.4%	$205.4M+868.7%	-$26.7M-140.4%	-$11.1M
Retained Earnings	-$972.4M+0.6%	-$978.1M0.0%	-$978.2M-13.2%	-$864.5M-40.7%	-$614.4M-11.9%	-$548.8M-19.4%	-$459.6M-18.0%	-$389.4M-47.7%	-$263.6M-51.3%	-$174.2M-110.9%	-$82.6M-196.8%	-$27.8M	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$101.6M-13.6%	$117.6M-14.9%	$138.2M-3.7%	$143.5M-0.2%	$143.8M-12.4%	$164.2M+17.4%	$139.8M-21.8%	$178.7M
Current Assets	$42.3M+33.0%	$31.8M-35.5%	$49.4M-4.2%	$51.5M+5.8%	$48.7M-26.3%	$66.1M+70.9%	$38.7M-47.0%	$72.9M
Cash & Equivalents	$15.6M-47.7%	$29.8M-34.8%	$45.8M-3.9%	$47.6M+5.0%	$45.4M-22.9%	$58.8M+91.1%	$30.8M-53.9%	$66.8M
Accounts Receivable	$274K+17.6%	$233K+48.4%	$157K-55.3%	$351K	N/A	N/A	$0	N/A
Total Liabilities	$67.1M-26.4%	$91.1M-3.0%	$94.0M-5.8%	$99.8M-10.0%	$110.8M-2.5%	$113.7M-9.8%	$126.0M-18.6%	$154.8M
Current Liabilities	$20.0M+3.6%	$19.3M+0.1%	$19.3M-13.9%	$22.4M-27.5%	$30.9M-1.2%	$31.3M-24.0%	$41.2M-36.4%	$64.8M
Total Equity	$34.5M+30.3%	$26.5M-40.1%	$44.2M+1.2%	$43.7M+32.6%	$33.0M-34.7%	$50.5M+266.1%	$13.8M-42.4%	$23.9M
Retained Earnings	-$987.7M+0.5%	-$992.3M-2.0%	-$972.4M-1.6%	-$957.1M+0.8%	-$965.3M-2.1%	-$945.4M+3.3%	-$978.1M-1.6%	-$962.5M

Not reported in any period shown, so not listed: Goodwill.

MCRB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MCRB annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Cash Flow	-$51.3M	$1.1M+100.8%	-$148.6M-26.6%	-$117.4M+48.7%	-$228.8M-3521.3%	$6.7M+107.1%	-$93.6M-22.3%	-$76.5M-21.7%	-$62.9M+16.8%	-$75.5M-272.0%	$43.9M+207.5%	-$40.8M-294.3%	-$10.4M-94.7%	-$5.3M
Capital Expenditures	$37K	$252K-33.7%	$380K-95.2%	$8.0M-18.8%	$9.8M+2.7%	$9.6M+1518.6%	$591K-41.0%	$1.0M-48.3%	$1.9M-58.6%	$4.7M-78.2%	$21.5M+392.7%	$4.4M+335.8%	$1.0M+475.3%	$174K
Free Cash Flow	-$51.3M	$865K+100.6%	-$149.0M-18.9%	-$125.3M+47.5%	-$238.6M-8191.8%	-$2.9M+96.9%	-$94.2M-21.5%	-$77.5M-19.6%	-$64.8M+19.2%	-$80.2M-457.6%	$22.4M+149.6%	-$45.2M-298.0%	-$11.4M-106.7%	-$5.5M
Investing Cash Flow	$187K	-$42K-100.0%	$142.3M+1244.7%	$10.6M-87.2%	$82.4M+28.6%	$64.1M+140.3%	-$158.9M-420.6%	-$30.5M-127.2%	$112.3M+101.6%	$55.7M+184.9%	-$65.6M	N/A	N/A	N/A
Financing Cash Flow	$14.9M	$13.9M+115.4%	-$90.4M-226.0%	$71.7M-44.7%	$129.6M+10901.9%	$1.2M-99.6%	$303.4M+251.9%	$86.2M+32075.7%	$268K+222.9%	$83K-96.1%	$2.1M	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$33K	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$22.4M-36.9%	-$16.4M-11.2%	-$14.7M-766.8%	$2.2M+116.6%	-$13.3M-149.4%	$26.9M+169.2%	-$38.9M-12.1%	-$34.7M
Capital Expenditures	$0	$0-100.0%	$29K+262.5%	$8K-95.6%	$181K+432.4%	$34K-62.2%	$90K-30.2%	$129K
Free Cash Flow	-$22.4M-36.9%	-$16.4M-11.0%	-$14.7M-770.6%	$2.2M+116.3%	-$13.5M-150.1%	$26.9M+169.0%	-$39.0M-12.0%	-$34.8M
Investing Cash Flow	$14K	$0-100.0%	$181K+2362.5%	-$8K+95.6%	-$181K-432.4%	-$34K+62.2%	-$90K-100.1%	$141.1M
Financing Cash Flow	$1.7M+300.7%	$428K-96.6%	$12.7M+20649.2%	$61K	$0-100.0%	$1.2M-32.1%	$1.7M+101.6%	-$110.9M

Not reported in any period shown, so not listed: Dividends Paid.

MCRB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

MCRB annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Margin	-11910.1%	N/A	N/A	-2524.1%	-44.5%	-265.3%	-208.3%	-354.8%	-284.7%	-426.5%	N/A	N/A	N/A
Net Margin	721.9%	N/A	N/A	-3509.5%	-45.3%	-268.3%	-203.7%	-350.0%	-278.4%	-420.7%	N/A	N/A	N/A
Return on Equity	12.9%+11.9pp	1.0%	N/A	-2319.9%-2270.1pp	-49.9%+1.1pp	-51.0%	N/A	N/A	-147.3%-78.2pp	-69.0%-42.4pp	-26.7%	N/A	N/A
Return on Assets	4.1%+4.0pp	0.1%+31.8pp	-31.7%+40.0pp	-71.7%-53.2pp	-18.5%+7.5pp	-26.0%+27.1pp	-53.1%+29.1pp	-82.1%-35.0pp	-47.2%-13.6pp	-33.6%-8.3pp	-25.3%-11.0pp	-14.2%	N/A
Current Ratio	2.56+1.6x	0.94-0.8x	1.78-0.5x	2.28-1.4x	3.69-2.1x	5.79+3.6x	2.180.0x	2.20-2.7x	4.90-1.6x	6.51-12.5x	19.01-3.4x	22.39	N/A
Debt-to-Equity	2.13-7.0x	9.14	N/A	4.64+4.5x	0.180.0x	0.14	N/A	N/A	2.12+1.1x	1.06+1.0x	0.06	N/A	N/A
FCF Margin	109.6%	N/A	N/A	-3347.9%	-2.0%	-283.6%	-224.7%	-229.2%	-249.8%	103.0%	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Margin	-2890.3%	-5839.9%	N/A	-6403.7%	N/A	N/A	N/A	N/A
Net Margin	622.4%	-5562.3%	N/A	2337.3%	N/A	N/A	N/A	N/A
Return on Equity	13.3%+88.4pp	-75.1%	N/A	18.8%+79.0pp	-60.3%-125.0pp	64.8%	N/A	371.1%
Return on Assets	4.5%+21.4pp	-16.9%	N/A	5.7%+19.5pp	-13.8%-33.7pp	19.9%	N/A	49.7%
Current Ratio	2.11+0.5x	1.65-0.9x	2.56+0.3x	2.30+0.7x	1.57-0.5x	2.11+1.2x	0.94-0.2x	1.12
Debt-to-Equity	1.94-1.5x	3.44+1.3x	2.13-0.2x	2.28-1.1x	3.36+1.1x	2.25-6.9x	9.14+2.7x	6.47
FCF Margin	-3042.7%	-4569.8%	N/A	626.2%	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Alpha Cognition ACOG

$212.3M

Greenwich Lifesciences Inc GLSI

$244.7M

Instil Bio, Inc. TIL

$51.4M

Sangamo Therapeutics Inc SGMO

$55.9M

Coherus CHRS

$219.4M

Where Seres Therapeutics Inc Ranks

Frequently Asked Questions

What is Seres Therapeutics Inc's annual revenue?

Seres Therapeutics Inc (MCRB) reported $789K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Seres Therapeutics Inc profitable?

Yes, Seres Therapeutics Inc (MCRB) reported a net income of $5.7M in fiscal year 2025.

What is Seres Therapeutics Inc's EBITDA?

Seres Therapeutics Inc (MCRB) had EBITDA of -$89.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Seres Therapeutics Inc's return on equity (ROE)?

Seres Therapeutics Inc (MCRB) has a return on equity of 12.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Seres Therapeutics Inc's free cash flow?

Seres Therapeutics Inc (MCRB) generated $865K in free cash flow during fiscal year 2025. This represents a 100.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Seres Therapeutics Inc's operating cash flow?

Seres Therapeutics Inc (MCRB) generated $1.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Seres Therapeutics Inc's total assets?

Seres Therapeutics Inc (MCRB) had $138.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Seres Therapeutics Inc's capital expenditures?

Seres Therapeutics Inc (MCRB) invested $252K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Seres Therapeutics Inc spend on research and development?

Seres Therapeutics Inc (MCRB) invested $49.1M in research and development during fiscal year 2025.

How many shares does Seres Therapeutics Inc have outstanding?

Seres Therapeutics Inc (MCRB) had 10M shares outstanding as of fiscal year 2025.

What is Seres Therapeutics Inc's current ratio?

Seres Therapeutics Inc (MCRB) had a current ratio of 2.56 as of fiscal year 2025, which is generally considered healthy.

What is Seres Therapeutics Inc's debt-to-equity ratio?

Seres Therapeutics Inc (MCRB) had a debt-to-equity ratio of 2.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Seres Therapeutics Inc's return on assets (ROA)?

Seres Therapeutics Inc (MCRB) had a return on assets of 4.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Seres Therapeutics Inc's Altman Z-Score?

Seres Therapeutics Inc (MCRB) has an Altman Z-Score of -11.53, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Seres Therapeutics Inc's Piotroski F-Score?

Seres Therapeutics Inc (MCRB) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Seres Therapeutics Inc's earnings high quality?

Seres Therapeutics Inc (MCRB) has an earnings quality ratio of 0.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.